blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4103214

EP4103214 - GENE THERAPY VECTORS FOR TREATING HEART DISEASE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  18.07.2024
Database last updated on 16.09.2024
FormerRequest for examination was made
Status updated on  18.11.2022
FormerThe international publication has been made
Status updated on  20.08.2021
Formerunknown
Status updated on  03.04.2021
Most recent event   Tooltip19.07.2024First examination report 
Applicant(s)For all designated states
Tenaya Therapeutics, Inc.
171 Oyster Point Boulevard
Suite 500
South San Francisco, Ca 94080 / US
[2022/51]
Inventor(s)01 / LOMBARDI, Laura
c/o Tenaya Therapeutics Inc. 171 Oyster Point
Boulevard Suite 500
South San Francisco, California 94080 / US
 [2022/51]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2022/51]
Application number, filing date21714285.011.02.2021
[2022/51]
WO2021US17699
Priority number, dateUS202062976160P13.02.2020         Original published format: US 202062976160 P
US202063047633P02.07.2020         Original published format: US 202063047633 P
[2022/51]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2021163357
Date:19.08.2021
Language:EN
[2021/33]
Type: A2 Application without search report 
No.:EP4103214
Date:21.12.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 19.08.2021 takes the place of the publication of the European patent application.
[2022/51]
Search report(s)International search report - published on:EP02.12.2021
ClassificationIPC:A61K38/00, A61P9/00, C07K14/47, C12N15/86, A61K48/00
[2022/51]
CPC:
A61P9/10 (EP,US); A61K38/00 (EP,IL); C12N15/86 (EP,IL,KR,US);
A61K48/0058 (EP,IL,KR,US); A01K67/0276 (EP); A61K48/005 (EP,IL);
A61K48/0075 (KR); A61P9/00 (EP,IL,KR); C07K14/4716 (EP,IL,KR);
C12N5/0657 (KR); C12N5/0696 (KR); A01K2217/075 (EP,IL);
A01K2227/105 (EP,IL); A01K2267/0375 (EP,IL); C07H21/04 (EP,US);
C12N15/8645 (US); C12N2310/20 (KR); C12N2750/14143 (EP,IL,KR);
C12N2830/008 (EP,IL,KR); C12N2830/50 (EP,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/51]
Extension statesBA13.09.2022
ME13.09.2022
Validation statesKH13.09.2022
MA13.09.2022
MD13.09.2022
TN13.09.2022
TitleGerman:GENTHERAPIEVEKTOREN ZUR BEHANDLUNG VON HERZKRANKHEITEN[2022/51]
English:GENE THERAPY VECTORS FOR TREATING HEART DISEASE[2022/51]
French:VECTEURS DE THÉRAPIE GÉNIQUE DE TRAITEMENT DE MALADIE CARDIAQUE[2022/51]
Entry into regional phase13.09.2022National basic fee paid 
13.09.2022Designation fee(s) paid 
13.09.2022Examination fee paid 
Examination procedure13.09.2022Examination requested  [2022/51]
13.09.2022Date on which the examining division has become responsible
31.03.2023Amendment by applicant (claims and/or description)
17.07.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
23.02.2023Renewal fee patent year 03
26.02.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]EP2792742  (UNIVERSITÄTSKLINIKUM HAMBURG EPPENDORF UKE [DE], et al) [X] 1-10,13-20,29,30,32-44 * par.1,14, 17, 48, 52, 68 * [Y] 11,12,27,28,31;
 [XY]US2018148488  (CHAMBERLAIN JEFFREY S [US], et al) [X] 1-3,5-9,13-15,21-23,25,29,33 * par.10, 251-254, SEQ ID NO.2 * [Y] 11,12,27,28,31;
 [P]  - "Sequence 2 from patent US 10479821.", EMBL, (20200214), Database accession no. MO519550, URL: EBI [P] * sequence . *
 [XY]  - MEARINI GIULIA ET AL, "Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice", NATURE COMMUNICATIONS, vol. 5, no. 1, doi:10.1038/ncomms6515, (20141202), URL: https://www.nature.com/articles/ncomms6515.pdf, XP055851801 [X] 1-3,5-10,17,18,20-26,29,30,32-37,39-41 * p.3 Fig.1(b), p.2 col.2 par.2 * [Y] 11,12,27,28,31

DOI:   http://dx.doi.org/10.1038/ncomms6515
 [XY]  - WERFEL STANISLAS ET AL, "Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase", CARDIOVASCULAR RESEARCH, GB, vol. 104, no. 1, doi:10.1093/cvr/cvu174, ISSN 0008-6363, (20141001), pages 15 - 23, URL: https://watermark.silverchair.com/cvu174.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAugwggLkBgkqhkiG9w0BBwagggLVMIIC0QIBADCCAsoGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM_hls76vkG2J_yWu0AgEQgIICmwvOncTTzu9xUQprS5UG1vb-NrGBLDXVss75ts7EvSv3V2EquMbkiJgHXqqJEX9Xb2xqENpWoQxSs2d1jGN2cRpYGO7cR, XP055851829 [X] 1,4 * p.16 col.1 par.4,p.16 col.1 par.6, p.17 col.2 par.1, Fig.2, p.17 col.2 par.2 * [Y] 11,12

DOI:   http://dx.doi.org/10.1093/cvr/cvu174
 [Y]  - MOSQUEIRA DIOGO ET AL, "CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy", EUROPEAN HEART JOURNAL, GB, vol. 39, no. 43, doi:10.1093/eurheartj/ehy249, ISSN 0195-668X, (20181114), pages 3879 - 3892, URL: https://watermark.silverchair.com/ehy249.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAukwggLlBgkqhkiG9w0BBwagggLWMIIC0gIBADCCAssGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMm8m_ABehOBRAatRPAgEQgIICnFgvOgmagJnnvIQkzzsCSWIfZ6P7p6SKmjiO2A233_fv_wh3TfO7cxSVI777Kl9IYoza2tkpUHnf_RwXhyo49q9puYfYn, XP055852374 [Y] 11,12 * p.3879 Abst., p.3880 col.1 par.2 - col.2 par.1, p.3889 col.2 par.1 *

DOI:   http://dx.doi.org/10.1093/eurheartj/ehy249
 [A]  - TRUONG DONG-JIUNN JEFFERY ET AL, "Development of an intein-mediated split-Cas9 system for gene therapy", NUCLEIC ACIDS RESEARCH, GB, vol. 43, no. 13, doi:10.1093/nar/gkv601, ISSN 0305-1048, (20150616), pages 6450 - 6458, URL: https://academic.oup.com/nar/article/43/13/6450/2414291, XP055791410 [A] 11,12 * p.6450 col.2 par.2 - p.6451 col.1 par.1 *

DOI:   http://dx.doi.org/10.1093/nar/gkv601
by applicantUS10889833
 WO2008124724
 US7892809
 US8632764
 US8889641
 WO2016054554
 US9475845
 US2016340393
 WO2017100671
 WO2017106236
 WO2017192750
 WO2017212019
 US2018066285
 US10011640
 WO2018152333
 WO2019028306
 US10480011
 WO2020117898
 WO2020191300
 WO2020198737
 US10894949
    - NEEDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443
    - PEARSONLIPMAN, Proc. Nat'l. Acad Sci. USA, (19880000), vol. 85, page 2444
    - ALTSCHUL et al., Nuc. Acids Res., (19770000), vol. 25, pages 3389 - 3402
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - GRAHAM et al., Virology, (19730000), vol. 52, page 456
    - CHU et al., Gene, (19810000), vol. 13, page 197
    - MARIANBRAUNWALD, Circ. Res., (20170000), vol. 121, pages 749 - 770
    - WALSH et al., Genet. Med., (20170000), vol. 19, pages 192 - 203
    - MARSTON et al., Circ. Res., (20090000), vol. 105, pages 219 - 222
    - VAN DIJK et al., Circulation, (20090000), vol. 119, pages 1473 - 1483
    - HELMS et al., Circ. Cardiovasc. Genet., (20140000), vol. 7, pages 434 - 443
    - ROTTBAUER et al., J. Clin. Invest., (19970000), vol. 100, pages 475 - 482
    - MOOLMAN et al., Circulation, (20000000), vol. 101, pages 1396 - 1402
    - VAN DIJK et al., Circ. Heart Fail, (20120000), vol. 5, pages 36 - 46
    - MCNAMARA et al., PLoS One, (20170000), vol. 12, page e0180064
    - BEVIS et al., Nat. Biotechnol., (20020000), vol. 20, no. 11, pages 83 - 87
    - MILLER, Nature, (20000000), vol. 357, pages 455 - 460
    - GRUNHAUS et al., Seminar in Virology, (19920000), vol. 200, no. 2, pages 535 - 546
    - BALAJI et al., J Surg Res, (20130900), vol. 184, no. 1, pages 691 - 698
    - PIRAS et al., Gene Therapy, (20160000), vol. 23, pages 469 - 478
    - ASOKARI et al., Hum Gene Ther, (20131100), vol. 24, no. 11, pages 906 - 913
    - POZSGAI et al., Mol Ther, (20170405), vol. 25, no. 4, pages 855 - 869
    - KOTTERMAN, M.A.D.V. SCHAFFER, "Engineering Adeno-Associated Viruses for Clinical Gene Therapy", Nature Reviews Genetics, (20140000), vol. 15, doi:10.1038/nrg3742, pages 445 - 451, XP055317129

DOI:   http://dx.doi.org/10.1038/nrg3742
    - IRIONS et al., Nature Biotechnology, (20070000), vol. 25, pages 1477 - 1482
    - CLARK et al., Hum Gene Ther, (19950000), vol. 6, pages 1329 - 41
    - DAMDINDORJ et al., PLoS One, (20140000), vol. 9, page e106472
    - PHILLIPS et al., Hypertension, (20020000), vol. 39, pages 651 - 5
    - KONKALMATT et al., Circ Cardiovasc Imaging, (20130000), vol. 6, pages 478 - 486
    - WU et al., Mol Ther, (20100000), vol. 18, pages 80 - 86
    - NASO et al., BioDrugs, (20170000), vol. 31, pages 317 - 334
    - CHOI et al., Curr Gene Ther, (20050000), vol. 5, pages 299 - 310
    - LIU et al., Curr Pharm Des, (20150000), vol. 21, pages 3248 - 56
    - ZINCARELLI et al., Mol. Ther., (20080000), vol. 16, pages 1073 - 1080
    - BIININGSRIVASTAVA, Mol Ther Methods Clin Dev, (20190000), vol. 12, pages 248 - 265
    - KATZ et al., Gene Ther, (20120000), vol. 19, pages 659 - 669
    - JASKI et al., JCardFail, (20090000), vol. 15, pages 171 - 181
    - MEARINI et al., Nat Commun, (20140000), vol. 5, page 5515
    - TOHYAMA et al., Cell Stem Cell, (20130000), vol. 12, no. 1, pages 127 - 37
    - LIAN et al., Proc Natl AcadSci USA, (20120000), vol. 109, no. 27, pages E1848 - 57
    - BURRIDGE PWHOLMSTROM AWU JC, Curr Protoc Hum Genet, (20150000), vol. 87, pages 2131 - 15
    - SCHLOSSAREK et al., Basic Res. Cardiol., (20120000), vol. 107, pages 1 - 13
    - LEKANNE DEPREZ et al., J Med Genet, (20060000), vol. 43, pages 829 - 832
    - XIN et al., Am J Med Genet Part A, (20070000), vol. 143A, pages 2662 - 2667
    - ZAHKA et al., Heart, (20080000), vol. 94, pages 1326 - 1330
    - MARZILIANO et al., Neonatology, (20120000), vol. 102, pages 254 - 258
    - WESSELS et al., Eur J Hum Genet, (20150000), vol. 23, pages 922 - 928
    - MEARINI et al., Nat. Commun., (20140000), vol. 5, page 5515
 US20030630127
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.